2025年3月19日 · My current research focus on investigating the IRE1alpha/XBP1 pathway of the unfolded protein response (UPR) as a therapeutic target for cancer treatment and developing novel therapeutic strategies to target this pathway. I have a solid background in cancer biology, drug discovery and bioinformatic analysis of large-scale omics data.

Dadi Jiang. Associate Professor RFA, UT MD Anderson Cancer Center. Verified email at mdanderson.org. Tumor Biology Translational Research Drug Discovery Metabolism Genomics. ... D Jiang, C Lynch, BC Medeiros, M Liedtke, R Bam, AB Tam, Z Yang, ... Scientific reports 6 (1), 33353, 2016. 38:

Dadi Jiang, Ph.D. Assistant Professor. Dr. Jiang has a solid background in cancer biology, drug discovery and bioinformatic analysis of large-scale omics data.

Dadi JIANG, Instructor | Cited by 1,734 | of Stanford University, CA (SU) | Read 43 publications | Contact Dadi JIANG

Recently, modulating this pathway with small molecule compounds has been demonstrated as a promising approach for disease therapy. In this review, we summarize a list of current investigational compounds targeting this pathway and their therapeutic features for treating human diseases.

Dive into the research topics where Dadi Jiang is active. These topic labels come from the works of this person. Together they form a unique fingerprint. Recent external collaboration on country/territory level. Dive into details by clicking on the dots or.

2024年5月15日 · We show that inositol-requiring enzyme 1 (IRE1α), an endoplasmic reticulum (ER) resident protein critical for the unfolded protein response (UPR), also determines cellular sensitivity to ferroptosis. Cancer and normal cells depleted of IRE1α gain resistance to ferroptosis, while enhanced IRE1α expression promotes sensitivity to ferroptosis.

Dadi Jiang: 3 Followers, 4 Following, 9 Research papers. Research interests: Trauma, Resuscitation, and Surgery.

2016年9月16日 · Through an in silico drug discovery approach based on protein-compound virtual docking, we identified the anthracycline antibiotic doxorubicin as an in vitro and in vivo inhibitor of XBP1...